Research progress of resistance to aromatase inhibitor therapy in breast cancer

李芷君; 徐兵河

doi:10.19401/j.cnki.1007-3639.2021.02.001

您当前的位置：

首页 >

文章列表页 >

Research progress of resistance to aromatase inhibitor therapy in breast cancer

更新时间：2026-01-27

- Research progress of resistance to aromatase inhibitor therapy in breast cancer
- China Oncology Vol. 31, Issue 2, Pages: 81-89(2021)
- 作者机构：
  
  国家癌症中心 / 国家肿瘤临床医学研究中心 / 中国医学科学院北京协和医学院肿瘤医院肿瘤内科,北京,100021
- 作者简介：
- 基金信息：
- DOI：10.19401/j.cnki.1007-3639.2021.02.001
  CLC： R737.9
- Published Online：02 March 2021，
  
  Published：02 March 2021
- 稿件说明：
移动端阅览
李芷君, 徐兵河. 乳腺癌芳香化酶抑制剂耐药的研究进展[J]. 中国癌症杂志, 2021, 31(2): 81-89.

李芷君, 徐兵河. Research progress of resistance to aromatase inhibitor therapy in breast cancer[J]. China Oncology, 2021, 31(2): 81-89.
李芷君, 徐兵河. 乳腺癌芳香化酶抑制剂耐药的研究进展[J]. 中国癌症杂志, 2021, 31(2): 81-89. DOI： 10.19401/j.cnki.1007-3639.2021.02.001.

李芷君, 徐兵河. Research progress of resistance to aromatase inhibitor therapy in breast cancer[J]. China Oncology, 2021, 31(2): 81-89. DOI： 10.19401/j.cnki.1007-3639.2021.02.001.

摘要

乳腺癌是女性常见的恶性肿瘤，约70%的患者为雌激素受体（estrogen receptor，ER）和（或）孕激素受体（progesterone receptor，PR）阳性，内分泌治疗是激素受体（hormone receptor，HR）阳性乳腺癌的主要治疗方式之一。近几十年来，内分泌治疗药物不断发展并应用于临床，乳腺癌患者的复发转移风险显著降低，预后得到长足改善。芳香化酶抑制剂（aromatase inhibitor，AI）在乳腺癌内分泌治疗中发挥重要作用，然而绝大部分患者会发生原发性或继发性耐药，因此克服内分泌治疗药物耐药对进一步提高临床疗效至关重要。从遗传学、表观遗传学及细胞内信号转导通路等方面对HR阳性乳腺癌患者AI治疗后耐药的机制及最新的研究进展进行综述，以期为临床诊疗及科研提供参考。

Abstract

Breast cancer is one of the most common malignancies in women. About 70% of patients are estrogen receptor (ER) and/or progesterone receptor (PR) positive. Endocrine therapy is one of the main treatments for hormone receptor (HR) positive breast cancer. In recent decades

endocrine therapy drugs have been continuously innovated and applied in clinical practice

the risk of recurrence/metastasis of breast cancer patients has been significantly reduced

and the prognosis has been greatly improved. Among them

aromatase inhibitors (AIs) play an important role in endocrine therapy for breast cancer. However

a large number of patients develop either primary or secondary endocrine therapy drug resistance. Therefore

it is very important to overcome endocrine therapy drug resistance to further improve clinical efficacy. This article reviewed the mechanisms and the latest research progress of drug resistance in HR-positive breast cancer after prior AI therapy from the aspects of genetics

epigenetics and intracellular signal transduction pathways

so as to provide some guidance for clinical diagnosis

treatment and scientific research.

关键词

Keywords

references

Views

5177

下载量

CSCD

Alert me when the article has been cited

提交

Tools

Publicity Resources

Mechanisms of resistance to EGFR TKIs and therapeutic perspectives in non-small cell lung cancer

Expert consensus on BRCA1/2 gene testing and clinical application in Chinese breast cancer patients (2025 edition)

New progress and prospect of breast cancer bone metastasis research from mechanism to clinic

Research progress on the mechanism of long chain non-coding RNA AFAP1-AS1 in cancer

NDRG2 increases bladder cancer cell sensitivity to cisplatin by inhibiting Bcl-2 expression

Related Author

Hongxia WANG

Yongmei YIN

Xichun HU

Zan SHEN

Jiahui WANG

Linlan JIANG

李志明

龙　凤

Related Institution

Committee of Breast Cancer Society, Chinese Anti-Cancer Association; Clinical Precision Medicine Professional Committee, Chinese Medical Doctor Association; Tumor Heterogeneity and Personalized Therapy Professional Committee, Chinese Anti-Cancer Association

上海交通大学附属第六人民医院肿瘤内科

甘肃中医药大学

甘肃省高校重大疾病分子医学与中医药防治研究省级重点实验室

空军军医大学唐都医院泌尿外科

AI问答

⁰